AIMS: Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double-blind, placebo-controlled out-patient trial tested topiramate for treating methamphetamine addiction. DESIGN:Participants (n = 140) were randomized to receive topiramate or placebo (13 weeks) in escalating doses from 25 mg/day [DOSAGE ERROR CORRECTED] to the target maintenance of 200 mg/day in weeks 6-12 (tapered in week 13). Medication was combined with weekly brief behavioral compliance enhancement treatment. SETTING: The trial was conducted at eight medical centers in the United States. PARTICIPANTS: One hundred and forty methamphetamine-dependent adults took part in the trial. MEASUREMENTS: The primary outcome was abstinence from methamphetamine during weeks 6-12. Secondary outcomes included use reduction versus baseline, as well as psychosocial variables. FINDINGS: In the intent-to-treat analysis, topiramate did not increase abstinence from methamphetamine during weeks 6-12. For secondary outcomes, topiramate reduced weekly median urine methamphetamine levels and observer-rated severity of dependence scores significantly. Subjects with negative urine before randomization (n = 26) had significantly greater abstinence on topiramate versus placebo during study weeks 6-12. Topiramate was safe and well tolerated. CONCLUSIONS:Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent.
RCT Entities:
AIMS: Topiramate has shown efficacy at facilitating abstinence from alcohol and cocaine abuse. This double-blind, placebo-controlled out-patient trial tested topiramate for treating methamphetamine addiction. DESIGN:Participants (n = 140) were randomized to receive topiramate or placebo (13 weeks) in escalating doses from 25 mg/day [DOSAGE ERROR CORRECTED] to the target maintenance of 200 mg/day in weeks 6-12 (tapered in week 13). Medication was combined with weekly brief behavioral compliance enhancement treatment. SETTING: The trial was conducted at eight medical centers in the United States. PARTICIPANTS: One hundred and forty methamphetamine-dependent adults took part in the trial. MEASUREMENTS: The primary outcome was abstinence from methamphetamine during weeks 6-12. Secondary outcomes included use reduction versus baseline, as well as psychosocial variables. FINDINGS: In the intent-to-treat analysis, topiramate did not increase abstinence from methamphetamine during weeks 6-12. For secondary outcomes, topiramate reduced weekly median urine methamphetamine levels and observer-rated severity of dependence scores significantly. Subjects with negative urine before randomization (n = 26) had significantly greater abstinence on topiramate versus placebo during study weeks 6-12. Topiramate was safe and well tolerated. CONCLUSIONS:Topiramate does not appear to promote abstinence in methamphetamine users but can reduce the amount taken and reduce relapse rates in those who are already abstinent.
Authors: Kyle M Kampman; Joseph R Volpicelli; Frank Mulvaney; Margaret Rukstalis; Arthur I Alterman; Helen Pettinati; Robert M Weinrieb; Charles P O'Brien Journal: Addict Behav Date: 2002 Mar-Apr Impact factor: 3.913
Authors: Bankole A Johnson; Nassima Ait-Daoud; Ahmed M Elkashef; Edwina V Smith; Roberta Kahn; Francis Vocci; Shou-Hua Li; Daniel A Bloch Journal: Int J Neuropsychopharmacol Date: 2007-05-01 Impact factor: 5.176
Authors: Kyle M Kampman; Helen Pettinati; Kevin G Lynch; Charles Dackis; Thorne Sparkman; Catherine Weigley; Charles P O'Brien Journal: Drug Alcohol Depend Date: 2004-09-06 Impact factor: 4.492
Authors: Bankole A Johnson; Nassima Ait-Daoud; Charles L Bowden; Carlo C DiClemente; John D Roache; Kevin Lawson; Martin A Javors; Jennie Z Ma Journal: Lancet Date: 2003-05-17 Impact factor: 79.321
Authors: Ahmed M Elkashef; Richard A Rawson; Ann L Anderson; Shou-Hua Li; Tyson Holmes; Edwina V Smith; Nora Chiang; Roberta Kahn; Frank Vocci; Walter Ling; Valerie J Pearce; Michael McCann; Jan Campbell; Charles Gorodetzky; William Haning; Barry Carlton; Joseph Mawhinney; Dennis Weis Journal: Neuropsychopharmacology Date: 2007-06-20 Impact factor: 7.853
Authors: Olga Rass; Annie Umbricht; George E Bigelow; Eric C Strain; Matthew W Johnson; Miriam Z Mintzer Journal: Psychol Addict Behav Date: 2014-11-03
Authors: Richard A Rawson; Joy Chudzynski; Larissa Mooney; Rachel Gonzales; Alfonso Ang; Daniel Dickerson; Jose Penate; Bilal A Salem; Brett Dolezal; Christopher B Cooper Journal: Drug Alcohol Depend Date: 2015-09-03 Impact factor: 4.492
Authors: Benjamin Ackerman; Ian Schmid; Kara E Rudolph; Marissa J Seamans; Ryoko Susukida; Ramin Mojtabai; Elizabeth A Stuart Journal: Addict Behav Date: 2018-10-25 Impact factor: 3.913
Authors: Annie Umbricht; Anthony DeFulio; Erin L Winstanley; D Andrew Tompkins; Jessica Peirce; Miriam Z Mintzer; Eric C Strain; George E Bigelow Journal: Drug Alcohol Depend Date: 2014-04-16 Impact factor: 4.492
Authors: M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas Journal: Pharmacol Rev Date: 2016-07 Impact factor: 25.468